RenovoRx initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of RenovoRx (RNXT) with a Buy rating and $3 price target RenovoRx is an early commercial-stage biotechnology company focused on developing a novel proprietary catheter system for targeted delivery of gemcitabine to treat locally advanced pancreatic cancer, the analyst tells investors in a research note. The firm says that with a total addressable worldwide market of approximately $740M, if successful, the company could generate revenues of $253M in 2034, growing from $4M in 2025. H.C. Wainwright says the shares are undervalued and could be attractive to a long-term investor.